Clinical trials: CRT Patients
Heart Failure
Assessment of Pacing Stimulus Conduction and Latency Measurements in CRT-D Patients
The study is designed to collect data on LV latency in CRT-D patients by the CRT-D and compare measurements to 12-lead ECG data
- Trial name
- BIO|PULSE (NCT03314675)
- Testing
- BIOTRONIK CRT-D
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 16 people
- Sponsor
- Biotronik SE & Co. KG
Squamous Cell Carcinoma of Head and Neck
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
This is a study comparing the activity of lapatinib versus placebo followed by chemoradiation. This study is designed to explore the effects of lapatinib monotherapy on apoptosis/necrosis, in pre-treatment and post-treatment…
- Trial name
- NCT00371566
- Testing
- Lapatinib oral tablets
- Where
- 9 sites in France, Greece and 3 more
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III)…
- Trial name
- LADOGA (NCT06606847)
- Testing
- Oleclumab, Durvalumab
- Where
- 11 sites in Russia
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
The primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
- Trial name
- NCT04459715
- Testing
- Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT)
- Where
- 288 sites in United States, Argentina and 24 more
- Volunteers
- 730 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rectal Neoplasms, Rectal Cancer
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
This study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with locally advanced rectal cancer (LARC).
- Trial name
- NCT05009069
- Testing
- Radiotherapy, Capecitabine, Fluorouracil
- Where
- 5 sites in China
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed…
- Trial name
- ADRIATIC (NCT03703297)
- Testing
- Durvalumab, Tremelimumab
- Where
- 183 sites in United States, Argentina and 17 more
- Volunteers
- 730 people
- Sponsor
- AstraZeneca
Heart Failure, LBBB Complete
The Effect of "Cerclage Pacing" for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT)
trans-coronary sinus intraseptal pacing (cerclage pacing)
- Trial name
- Cerclage-CRT (NCT03438591)
- Testing
- Medtronic 4196 lead
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Tau-MEDICAL Co., Ltd.
Cancer
Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer
1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced…
- Trial name
- NCT00273546
- Testing
- XRP6976 (Docetaxel/Taxotere)
- Where
- 6 sites in United States, Argentina and 4 more
- Volunteers
- 500 people
- Sponsor
- Sanofi
Glioblastoma, Small Cell Glioblastoma
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ReACT (NCT01498328)
- Testing
- Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
- Where
- 45 sites in United States
- Volunteers
- 127 people
- Sponsor
- Celldex Therapeutics
Neovacular Age-related Macular Degeneration
UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept.
- Trial name
- UNRAVEL (NCT01988662)
- Testing
- Neovascular Age-related Macular Degeneration
- Where
- 24 sites in Israel, Malaysia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.
- Trial name
- NCT05635734
- Testing
- Azeliragon 5 mg, Azeliragon 10 mg, Azeliragon 20 mg
- Where
- 4 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Cantex Pharmaceuticals
Change in LDS Signals Due to Cardiac Synchronization Therapy
Changes in Doppler Signals From the Lung Due to Cardiac Resynchronization in Heart Failure Patients
Study Purpose and Rationale The purpose of this study is to evaluate the lung Doppler signals changes during cardiac resynchronization procedure.
- Trial name
- NCT02179203
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Echosense Ltd.
Heart Failure
Selected Site Pacing to Avoid Phrenic Nerve Stimulation in Cardiac Resynchronization Patients With Quadripolar Left Ventricular Leads
Cardiac resynchronization (CRT) therapy is well established for treatment of patients with severe heartfailure, reduced left ventricular (LV) function and ventricular dyssynchrony.
- Trial name
- EffaceQ (NCT01484613)
- Testing
- quadripolar LV lead (Quartet)
- Where
- 16 sites in Germany
- Volunteers
- 337 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Heart Failure NYHA Class II
Heart Failure Management for Patient With CIED Remotely Monitored
This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction (HFrEF)
- Trial name
- PROACT-HF (NCT07247032)
- Testing
- SmartSignalHF, HF RM standard of care
- Where
- France
- Volunteers
- 1,132 people
- Sponsor
- Implicity
Heart Failure
Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study
Goal is to examine the efficy of Cardiac Resynchronization Therapy in heart failure patients with narrow QRS complex and optimized medical treatment but echocardiographic desynchronization detection as well as the positve…
- Trial name
- CRT-Narrow (NCT00821938)
- Testing
- LV dp/dt pressure measurement
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Arrhythmia, Sinus Node Disease
PANORAMA Observational Study
To construct a computerized database of national profiles and epidemiological data on patients wearing Medtronic implantable pacemakers and cardioverter defibrillators (both with or without cardiac resynchronization therapy)…
- Conditions
- Arrhythmia, Sinus Node Disease, Heart Failure, Heart Block
- Trial name
- NCT00382525
- Testing
- Cardiac Rhythm Management device
- Where
- 27 sites in Belgium, India and 4 more
- Volunteers
- 8,586 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence
The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
- Trial name
- NCT05860348
- Testing
- Barostim™ System
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- CVRx, Inc.
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer
- Trial name
- NCT03237325
- Testing
- SGX942
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 266 people
- Sponsor
- Soligenix
Small-cell Lung Cancer
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.
The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease…
- Trial name
- NCT06789796
- Testing
- Iparomlimab and Tuvonralimab (QL1706), QL1604
- Volunteers
- 636 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.